Table 1.
Study Characteristics of Included Studies.
| Author (Ref.) | Year of publication | Country | Type of study | Instrument used to quantify QOL | No. of patients included in the study (n) | Mean age of patients included in the study | Tumor stage of patients included in the study | Tumor subsite (% of included patients, if available) | Mean follow-up duration | Adjuvant radiotx (% of included patients) | Adjuvant chemotx (% of included patients) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Airoldi et al 13 | 2011 | Italy | C | EORTC QLQ-C30 and EORTC QLQ-H&N35 | 36 | Info not available | I to IVB | OC | 63 ± 18 mo | 100% | Info not available |
| Borggreven et al 14 | 2007 | Netherlands | L | EORTC QLQ-C30 and EORTC QLQ-H&N35 | 80 | 58 | Info not available | OC (47%), OPX (53%) | Info not available | 93% | Info not available |
| Bozec et al 15 | 2018 | France | L | EORTC QLQ-C30 and EORTC QLQ-H&N35 | 58 | 61.5 | II to IV | OPX | >1 y | 76% | 35% |
| Bozec et al 16 | 2020 | France | C | EORTC QLQ-C30 and EORTC QLQ-H&N35 | 64 | 75.4 | Info not available | OC (75%), OPX (25%) | >1 y | 78% | 17% |
| Bozec et al 17 | 2009 | France | L | EORTC QLQ-C30 and EORTC QLQ-H&N35 | 41 | 68% had less than 70 y old | II to IV | OC (51%), OPX (49%) | >1 y | 75% | 48% |
| Bozec et al 18 | 2008 | France | L | EORTC QLQ-C30 and EORTC QLQ-H&N35 | 65 | 61.2 | Info not available | OC/OPX (87.3%), HPX (11.1%), sinus (1.6%) | >1 y | 81.50% | Info not available |
| Chang et al 19 | 2012 | Taiwan | L | UW-QOL | 32 | 53.53 | Info not available | OC | >2 y | Info not available | Info not available |
| Dimovska et al 20 | 2016 | England | L | UW-QOL | 96 (34 evaluation of QOL) | 84 | I to IV | Skin, OC, LX | Info not available | Info not available | Info not available |
| Elfring et al 21 | 2014 | Canada | L | EORTC QLQ-H&N35 | 30 | Info not available | I to III | OPX | Info not available | 36.70% | 56.60% |
| Hartl et al 22 | 2009 | France | L | EORTC QLQ-H&N35 | 9 | 51 | Info not available | OC, OPX | 43 mo | 77.80% | 22.20% |
| Jimenez et al 23 | 2021 | USA | C | UW-QOL | 80 | 60 | I to IVB | OC | 6 mo to 17 y | 38% | 41% |
| Klug et al 24 | 2002 | Austria | L | EORTC QLQ-C30 and EORTC QLQ-H&N35 | 67 | 56 | Info not available | OC, OPX | Info not available | 100% | 100% |
| Lahtinen et al 25 | 2018 | England | C | EORTC QLQ-C30 and EORTC QLQ-H&N35 and UW-QOL | 53 | 62.7 | Info not available | OC (43.4%), maxilla (9.4%), mandible (20.8%), LX/pharynx (3.8%), skin (3.8%), palate (7.5%), buccal mucosa (9.4%), other (2.6%) | >1 y | 67.90% | Info not available |
| Markkanen-Leppänen et al 26 | 2006 | Finland | L | UW-QOL | 44 | 56.2 | II to IV | OC (64%), pharynx (29%), HPX (7%) | >1 y | 88% | 9% |
| Momeni et al 27 | 2013 | USA | L | EORTC QLQ-C30 and EORTC QLQ-H&N35 and UW-QOL | 21 | 57.9 | Info not available | OC, OPX, esophagus, sinus, skin | >1 y | 61.90% | Info not available |
| Oskam et al 28 | 2010 | Nether-lands | L | EORTC QLQ-C30 and EORTC QLQ-H&N35 | 80 (55 evaluation of QOL) | 58 | II to IV | OC (47%), OPX (53%) | > 6 mo | 93% | Info not available |
| Pierre et al 29 | 2014 | France | L | EORTC QLQ-C30 and EORTC QLQ-H&N35 | 80 | Info not available | Info not available | OC (46%), OPX (54%) | >1 y | 69% | Info not available |
| Rhemrev et al 30 | 2007 | Nether-lands | L | EORTC QLQ-H&N35 | 85 | 57 | Info not available | OC | 43 mo | 79% | Info not available |
| Segna et al 31 | 2018 | Italy | L | SF-36 and SF-12 | 30 | 65.5 | I/II: 33.3% III/IV: 66.7% | OC, skin | >1 y | 60% | 16.70% |
| Smith et al 32 | 2006 | Australia | L | FACT-G, FACT-H&N, UW-QOL, and PSS-HN | 63 | 65.2 | Info not available | OC | >1 y | 47.60% | Info not available |
| Tamer et al 33 | 2020 | China | L | MDADI, EAT-10, and FACT-H&N | 256 | 46.7 | I: 29.1% II: 48.3% III: 22.3% IV: 0.4% | OC | >1 mo | 71.70% | 10.20% |
| Yang et al 34 | 2016 | China | C | UW-QOL | 61 (28 free flap) | Info not available | Info not available | OC | >1 y | 68% | Info not available |
Abbreviations: C, cross-sectional; EAT-10, Eating Assessment Tool; EORTC, European Organization for Research and Treatment of Cancer Questionnaires; FACT-G, Functional Assessment of Cancer Therapy – General; FACT-H&N, Functional Assessment of Cancer Therapy—Head and Neck; HPX, hypopharynx; L, longitudinal; LX, larynx; MDADI, M.D. Anderson Dysphagia Inventory; OC, oral cavity; OPX, oropharynx; QOL, quality of life; UW-QOL, University of Washington Quality of Life Questionnaire..